Harlan L. Pietz

A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection

Lesia Dropulic, Makinna Oestreich, Harlan L. Pietz et al. · The Journal of Infectious Diseases · 2019 · 63 citations · Full text

Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy

Harshana S. De Silva Feelixge, Daniel Stone, Harlan L. Pietz et al. · Antiviral Research · 2015 · 43 citations · Full text

Treatment-resistant Infectious Hiv, Human Retrovirus, Immunology +8

Structure-based discovery of CFTR potentiators and inhibitors

Fangyu Liu, Anat Levit, Jesper Levring et al. · Cell · 2024 · 27 citations · Full text

Pharmaceutical Science, Drug Target, Chemical Biology +17

A macrocyclic peptide inhibitor traps MRP1 in a catalytically incompetent conformation

Harlan L. Pietz, Ata Abbas, Z.L. Johnson et al. · Proceedings of the National Academy of Sciences · 2023 · 20 citations · Full text

A Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals

Lesia Dropulic, Kening Wang, Makinna Oestreich et al. · Open Forum Infectious Diseases · 2017 · 11 citations · Full text

Immunodeficiencies, Immunology, Hsv Seronegative Individuals +23